
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is expected to generate significant revenue by 1st half of 2026 with its existing BARDA contract and commercial launch of DeepView System. The company has a strong potential to improve patient outcomes and efficiency of clinical studies in the large and under-penetrated Advanced Wound Care market. With a projected annual revenue growth rate of 69% and a license model expected to drive recurring revenue at high margins, Spectral AI has the potential to become a stable and growing company in the MedTech industry.
Bears say
Spectral AI is currently facing delays and uncertainty in its revenue guidance, making it difficult for investors to accurately assess the company's financial performance. Additionally, the company's reliance on a single indication (burns) and one government contract (BARDA PBS) could make it vulnerable to changes in the regulatory and political climate. Furthermore, the company's current valuation seems inflated compared to its peers, making it a risky investment option for those looking for long-term growth.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares